• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Symptomatic Improvement Observed Within 2 Days of Etrasimod Induction Therapy: Results From ELEVATE UC 52 and ELEVATE UC 12 Studies in Patients With Ulcerative Colitis.

出版信息

Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 9):6-7.

PMID:38445183
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10910374/
Abstract
摘要

相似文献

1
Symptomatic Improvement Observed Within 2 Days of Etrasimod Induction Therapy: Results From ELEVATE UC 52 and ELEVATE UC 12 Studies in Patients With Ulcerative Colitis.在etrasimod诱导治疗的2天内观察到症状改善：溃疡性结肠炎患者的ELEVATE UC 52和ELEVATE UC 12研究结果。
Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 9):6-7.
2
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.埃特拉莫德用于溃疡性结肠炎的诱导和维持治疗（ELEVATE）：两项随机、双盲、安慰剂对照的3期研究。
Lancet. 2023 Apr 8;401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2. Epub 2023 Mar 2.
3
Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12.乌司奴单抗治疗溃疡性结肠炎患者的健康相关生活质量结局：来自ELEVATE UC 52和ELEVATE UC 12数据的事后分析
Inflamm Bowel Dis. 2024 Sep 26. doi: 10.1093/ibd/izae229.
4
Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials.在日本溃疡性结肠炎患者中etrasimod的疗效和安全性：来自3期ELEVATE UC 12和ELEVATE UC 40日本试验的数据。
Digestion. 2024 Sep 24:1-9. doi: 10.1159/000541383.
5
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.在 ELEVATE UC 52 和 ELEVATE UC 12 试验中，先前的生物制剂或 Janus 激酶抑制剂治疗对依特司莫单抗疗效和安全性的影响。
J Crohns Colitis. 2024 Nov 4;18(11):1780-1794. doi: 10.1093/ecco-jcc/jjae079.
6
Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod.接受埃曲莫德治疗的溃疡性结肠炎患者的内镜、组织学及综合终点指标
Clin Gastroenterol Hepatol. 2025 Feb;23(2):341-350.e6. doi: 10.1016/j.cgh.2024.07.010. Epub 2024 Jul 31.
7
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.在中重度孤立性直肠炎患者中的疗效和安全性：来自 3 期 ELEVATE UC 临床项目的结果。
J Crohns Colitis. 2024 Aug 14;18(8):1270-1282. doi: 10.1093/ecco-jcc/jjae038.
8
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program.埃特拉莫德对粪便钙卫蛋白和高敏C反应蛋白的影响：ELEVATE UC临床项目的结果
Inflamm Bowel Dis. 2025 Apr 10;31(4):923-934. doi: 10.1093/ibd/izae111.
9
Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program.埃特拉莫德在溃疡性结肠炎中的无皮质类固醇疗效、联用皮质类固醇对疗效和安全性的影响以及皮质类固醇节省效应：ELEVATE UC临床项目分析
J Crohns Colitis. 2025 Mar 5;19(3). doi: 10.1093/ecco-jcc/jjae150.
10
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme.依特司莫单抗治疗溃疡性结肠炎：ELEVATE UC 临床项目中感染事件的分析。
J Crohns Colitis. 2024 Oct 15;18(10):1596-1605. doi: 10.1093/ecco-jcc/jjae060.

引用本文的文献

1
Highlights in Ulcerative Colitis From the American College of Gastroenterology 2023 Annual Scientific Meeting: Commentary.美国胃肠病学会2023年年度科学会议溃疡性结肠炎亮点：评论
Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 9):13-18.

本文引用的文献

1
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.埃特拉莫德用于溃疡性结肠炎的诱导和维持治疗（ELEVATE）：两项随机、双盲、安慰剂对照的3期研究。
Lancet. 2023 Apr 8;401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2. Epub 2023 Mar 2.
2
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.STRIDE-II：炎症性肠病（STRIDE）国际研究组织（IOIBD）治疗靶点选择更新：确定炎症性肠病靶向治疗策略的治疗目标。
Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19.
3
Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey.溃疡性结肠炎：疾病负担、对日常生活的影响以及不愿咨询医疗专业人员：一项日本互联网调查的结果
Inflamm Intest Dis. 2020 Feb;5(1):27-35. doi: 10.1159/000505092. Epub 2020 Feb 3.